Maidenhead, England (ots/PRNewswire) - --Rare Disease Day takes place on 28 February 2013 and this year's theme focuses on 'Rare Disorders without Borders'-- --ViroPharma Incorporated is an international biopharmaceutical company committed to supporting patients with serious diseases for which there is an unmet medical need-- ViroPharma Incorporated , an international biopharmaceutical company committed to supporting ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - - Global Initiatives Underscore Company's Long-Term Commitment to the Rare Disease Community Shire plc today announced its support of Rare Disease Day, joining patients, healthcare providers, and patient organizations around the world to support a day that focuses attention on rare diseases as a public health issue, and highlights the need for more understanding and awareness ...
http://resources.euroadhoc.com/us/E2sWCuEm http://resources.euroadhoc.com/us/1Vsl1JqX http://resources.euroadhoc.com/us/xjnZF0tD http://resources.euroadhoc.com/us/pfwE96bs issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: ...
Paris, France (ots) - - Data presented at ATTD by Sanofi will focus on the company's integrated portfolio of therapeutic solutions, blood glucose monitoring, insulin delivery and contributions to advancing diabetes research - Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that its comprehensive portfolio of ...
Mumbai, India And Baltimore (ots/PRNewswire) - Approval to add to growing SUPRAX(R) Franchise Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received approval for SUPRAX(R) (Cefixime) for Oral Suspension, 500 mg/5mL from the United States Food and Drugs Administration (FDA). Lupin expects to commence ...
Lyon, France (ots/PRNewswire) - Upon approval Hexyon will be the only fully liquid, ready-to-use 6-in-1 paediatric vaccine in Europe Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur in Europe, announced today that their innovative 6-in-1 paediatric vaccine Hexyon has been recommended for marketing authorisation by the European Medicines Agency's ...
Cambridge, England (ots/PRNewswire) - NOT INTENDED FOR MEDIA IN THE NETHERLANDS -Treatment with bendamustine plus rituximab (B-R) doubles progression free survival (PFS) compared with current standard of care CHOP-R (69.5 versus 31.2 months; ...
http://resources.euroadhoc.com/us/WuYAhdmi http://resources.euroadhoc.com/us/zIy1Ktwc issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: ...
Zug, Switzerland (ots/PRNewswire) - Cardiorentis has initiated the first-ever acute heart failure (AHF) Phase III trial to be specifically designed to assess the effect of early treatment on cardiovascular mortality. TRUE-AHF (TRial of Ularitide's Efficacy and safety in patients with Acute Heart Failure) aims to ...
Shire Pharmaceuticals Group Plc
Philadelphia (ots/PRNewswire) - Shire plc , announces that its subsidiary, Shire LLC, has settled all pending litigation with Impax Laboratories, Inc. ("Impax") over Shire's supply of an authorized generic version of Adderall XR. Shire has been supplying Impax with authorized generic Adderall XR since October 2009 pursuant to a supply agreement between the parties. In ...
http://resources.euroadhoc.com/us/Ojrskc2e http://resources.euroadhoc.com/us/YxkzoEfd issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: ...
Munich (ots/PRNewswire) - The registry plans to gather data from more than 4,000 patients with VTE across seven European countries, providing insights into the clinical management of a disease that is a leading cause of morbidity and mortality[1] Daiichi Sankyo Europe GmbH announced the enrolment of the first ...
Paris (ots/PRNewswire) - - Sanofi portfolio expands to offer first once-a-day prandial GLP-1 receptor agonist - Sanofi announced today that the European Commission has granted Marketing Authorisation in Europe for Lyxumia(R) (lixisenatide). Lyxumia(R), the first once-daily prandial GLP-1 receptor agonist, is ...
Brussels (ots/PRNewswire) - The winners of the EU Health Prize for Journalists were announced at an awards ceremony in Brussels yesterday evening. German journalist, Tobias Zick received the prestigious special prize for articles on smoking. Zick, writing for NEON magazine was celebrated for his in-depth article ...
http://resources.euroadhoc.com/us/E53tdyIt issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: ...
Lausanne, Switzerland And Mechelen, Belgium (ots/PRNewswire) - Biocartis, a molecular diagnostics company developing and commercializing innovative, high quality, easy to use platforms and clinically relevant oncology assays, announced today that Inge Basteleurs has joined the company as General Counsel. Inge will be a member of Biocartis' Executive Committee and a ...
Lyon, France (ots/PRNewswire) - Appointment marks new chapter in vaccine advocacy in Europe Andrea Rappagliosi, Vice President of Market Access, Health Policy & Medical Affairs at Sanofi Pasteur MSD has been appointed President of Vaccines Europe as of 1st January 2013. Vaccines Europe is the group representing vaccine manufacturers within the European Federation of ...
Astellas Pharma Europe Limited
Chertsey, England (ots/PRNewswire) - A new treatment, BETMIGA(TM) (mirabegron) has received approval from the European Commission (EC) for the treatment of overactive bladder (OAB) symptoms in adults.[1] Mirabegron represents the first new class of oral treatment in OAB for over 30 years. Currently around half of patients discontinue OAB treatment after only three ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - - HGT Pipeline Enhanced with Protein Replacement Therapy Being Investigated for the Treatment of Dystrophic Epidermolysis Bullosa Shire plc , announces that it has signed an agreement to acquire Lotus Tissue Repair, Inc. of Cambridge, MA, a privately held biotechnology company developing the first and only protein replacement therapy currently being investigated for the ...
Hatfield, England (ots/PRNewswire) - Eisai today launches Fycompa(R) (perampanel) in Norway as a treatment for partial-onset seizures, with or without secondarily generalised seizures, in people with epilepsy aged 12 years and older.[1] Perampanel is the first in an entirely new class of treatment for uncontrolled partial epilepsy, the most common form of the ...
Geneva (ots/PRNewswire) - Merck Serono, a division of Merck, Darmstadt, Germany, announced that the U.S. Food and Drug Administration (FDA) approved Rebif(R) Rebidose(R) (interferon beta-1a), a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS). "Over the past two decades, ...
Hatfield, England (ots/PRNewswire) - Child friendly formulation set to aid administration for the treatment of Lennox-Gastaut syndrome Inovelon(R) (rufinamide) oral suspension for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four years and older is launched today in Spain. As many patients who receive the orphan ...
http://resources.euroadhoc.com/us/IPI4rsuU issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: Berlin, Open ...
Marlow, England (ots/PRNewswire) - Data demonstrates BOTOX(R)injections can reduce urinary leakage episodes for up to six months in patients who have had an inadequate response to, or are intolerant of, anticholinergic medication Today, Allergan Inc. announced that BOTOX(R)has received a positive opinion from the ...
http://resources.euroadhoc.com/us/KN1K9flc issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
Shire Pharmaceuticals Group Plc
Nyon, Switzerland (ots/PRNewswire) - Shire plc today announces a positive outcome from the European Decentralised Procedure (DCP) for Elvanse(R) (to be known as Tyvense(R) in Ireland). Elvanse is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children ...
Amsterdam (ots/PRNewswire) - Norgine BV (Amsterdam) and SpePharm Holding BV (Amsterdam) announced today that they have concluded a broad collaboration agreement under which the two companies have invested in a 50:50 joint venture, SpePharm AG, which has acquired the entire product portfolio of SpePharm Holding, including Savene(R), MuGard(R), Xerotin(R), PROther(R) and the Dantrium(R) brands. The new joint venture will ...
Raritan, New Jersey (ots/PRNewswire) - Veridex, LLC today announced approval from the China State Food & Drug Administration (SFDA) for the CellSearch(R) circulating tumor cell (CTC) test as an in vitro diagnostic for women with metastatic breast cancer. This makes CellSearch(R) the first and only approved CTC test for cancer patients in China, which is the seventh ...
Lausanne, Switzerland (ots/PRNewswire) - - Capital to be used to commercialize recently launched DMAT platform, validate APOLLO platform and build proprietary oncology content on both platforms - Strong support from internal shareholders and a recognition of our achievements Biocartis, a molecular diagnostics company developing and commercializing innovative, high ...
Bristol-Myers Squibb GmbH & Co. KGaA
Paris (ots/PRNewswire) - My CML Life Online Resource Centre Empowers and Guides Patients with CML Through Different Stages of Their Journey Bristol-Myers Squibb Company today announced the introduction of "My CML Life", a disease awareness website for patients with chronic myeloid leukaemia (CML). In recognition of ...